#Clinical Research #Retina #InFocus

InFocus Clinical Research: A Rising Star in Healthcare

InFocus Clinical Research has made headlines by securing the 434th position on the prestigious 2025 Inc. 5000 list, marking a remarkable leap from its previous ranking of 724 in 2024. This annual list ranks the fastest-growing privately-held companies across the United States, and InFocus's ascent highlights its significant impact in the healthcare sector, particularly in the retina specialty space.

Founded in 2015, InFocus Clinical Research is dedicated exclusively to clinical research related to retinal diseases. The company was established by experts in the field of retina, bringing together a wealth of therapeutic knowledge and operational agility. This unique focus has allowed InFocus to build a strong reputation and foster enduring relationships with leading retinal research sites, enhancing its capability to deliver high-performing clinical trials.

Achievements and Recognitions

In addition to its national recognition in the Inc. 5000 list, InFocus has also earned notable accolades within its local and state contexts. The company ranked:

• - No. 11 in the Nashville metropolitan area
• - No. 13 in the state of Tennessee
• - No. 45 in the Healthcare and Medical category nationwide

These rankings are a testament to the company’s unwavering commitment to quality partnerships and revolutionary advancements in retina research. CEO Brad Doerschuk stated, "This recognition reflects not only rapid growth but our unwavering commitment to quality partnerships and advancing retina research."

Innovative Approach and Future Vision

One of the key factors contributing to InFocus’s success is its comprehensive understanding of clinical research tailored for retina diseases. The company has developed a unique model that emphasizes therapeutic focus, site alignment, and a differentiating approach that has a tangible impact in the industry.

InFocus utilizes its proprietary Real-Time Intelligence (RTI) database, which encompasses over 400 global retina clinics, enabling smarter site selection, enhanced enrollment efforts, and more agile trial execution. Such capabilities are essential as the complexity of clinical trials evolves and new therapies emerge.

“We’re proud of the progress we’ve made, but we’re even more energized by what’s ahead,